Search

Your search keyword '"Mandeep K. Banwait"' showing total 3 results
Start Over Author "Mandeep K. Banwait"
3 results on '"Mandeep K. Banwait"'

1. Supplementary Data from Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion

Author

Lecia V. Sequist, Aaron N. Hata, Beni Wolf, Sai-Hong I. Ou, Corinne Clifford, Erica K. Evans, Alice T. Shaw, Rebecca S. Heist, A. John Iafrate, Mari Mino-Kenudson, Dora Dias-Santagata, Richard B. Lanman, Rebecca J. Nagy, Jessica J. Lin, Varuna Nangia, Amanda K. Riley, Satoshi Yoda, Wenjia Su, Subba R. Digumarthy, Mandeep K. Banwait, Nicolas Marcoux, Viola W. Zhu, Inga T. Lennes, Justin F. Gainor, Jochen K. Lennerz, Hideko Isozaki, and Zofia Piotrowska

Abstract

Supplementary Data and Methods

Published
2023
Full Text
View/download PDF

2. Supplementary Figures from Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion

Author

Lecia V. Sequist, Aaron N. Hata, Beni Wolf, Sai-Hong I. Ou, Corinne Clifford, Erica K. Evans, Alice T. Shaw, Rebecca S. Heist, A. John Iafrate, Mari Mino-Kenudson, Dora Dias-Santagata, Richard B. Lanman, Rebecca J. Nagy, Jessica J. Lin, Varuna Nangia, Amanda K. Riley, Satoshi Yoda, Wenjia Su, Subba R. Digumarthy, Mandeep K. Banwait, Nicolas Marcoux, Viola W. Zhu, Inga T. Lennes, Justin F. Gainor, Jochen K. Lennerz, Hideko Isozaki, and Zofia Piotrowska

Abstract

Supplementary Figures

Published
2023
Full Text
View/download PDF

3. Landscape of Acquired Resistance to Osimertinib in

Author

Zofia, Piotrowska, Hideko, Isozaki, Jochen K, Lennerz, Justin F, Gainor, Inga T, Lennes, Viola W, Zhu, Nicolas, Marcoux, Mandeep K, Banwait, Subba R, Digumarthy, Wenjia, Su, Satoshi, Yoda, Amanda K, Riley, Varuna, Nangia, Jessica J, Lin, Rebecca J, Nagy, Richard B, Lanman, Dora, Dias-Santagata, Mari, Mino-Kenudson, A John, Iafrate, Rebecca S, Heist, Alice T, Shaw, Erica K, Evans, Corinne, Clifford, Sai-Hong I, Ou, Beni, Wolf, Aaron N, Hata, and Lecia V, Sequist

Subjects
Adult, Male, congenital, hereditary, and neonatal diseases and abnormalities, endocrine system, Lung Neoplasms, endocrine system diseases, Oncogene Proteins, Fusion, Article, Cohort Studies, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Humans, neoplasms, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Acrylamides, Aniline Compounds, Proto-Oncogene Proteins c-ret, Middle Aged, respiratory tract diseases, ErbB Receptors, Cytoskeletal Proteins, Drug Resistance, Neoplasm, Mutation, Female
Abstract

We present a cohort of 41 patients with osimertinib resistance biopsies, including two with an acquired CCDC6-RET fusion. While RET fusions have been identified in resistant EGFR-mutant NSCLC, their role in acquired resistance to EGFR inhibitors is not well described. To assess the biological implications of RET fusions in an EGFR-mutant cancer, we expressed CCDC6-RET in PC9 (EGFR del19) and MGH134 (EGFR L858R/T790M) cells and found that CCDC6-RET was sufficient to confer resistance to EGFR-TKIs. The selective RET inhibitors BLU-667 or cabozantinib resensitized CCDC6-RET-expressing cells to EGFR inhibition. Finally, we treated two patients with EGFR-mutant NSCLC and RET-mediated resistance with osimertinib and BLU-667. The combination was well-tolerated and led to rapid radiographic response in both patients. This study provides proof-of-concept that RET fusions can mediate acquired resistance to EGFR TKIs and that combined EGFR and RET inhibition with osimertinib/BLU-667 may be a well-tolerated and effective treatment strategy for such patients.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results